Reduction of PRC2 activity supports survival of TNBC cancer cells to cytotoxic treatments
Ontology highlight
ABSTRACT: Basal-like breast cancer generally shows a good response to conventional cytotoxic but rapidly develops a resistant phenotype. To better understand the epigenetic changes underlying the acquisition of resistant properties, we treated the murine basal-like mammary carcinoma cell line G-2 for 48 hours with sublethal combination chemotherapy (Cyclophosphamide, Adriamycin, 5-Fluorouracil) and subsequently subjected them to RNA- and ChIP-sequencing.
INSTRUMENT(S): Illumina HiSeq 2500
ORGANISM(S): Mus musculus
SUBMITTER: Florian Wegwitz
PROVIDER: E-MTAB-9547 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
ACCESS DATA